Case Overview
The RDDC RNA Splicing Prediction Model plays a crucial role in the molecular diagnosis of rare, lethal skeletal dysplasias. In a genetic analysis of a family with Achondrogenesis Type IA (ACGIA), this tool successfully predicted the functional consequences of a novel variant located at a canonical splice site within the TRIP11 gene. This in silico prediction provided vital evidence for clarifying the variant's pathogenicity, aiding prenatal diagnosis and genetic counseling.
Research Challenge: WES Identifies a Splice Site VUS
This study focused on a case where pregnancy was terminated due to suspected lethal skeletal dysplasia detected via ultrasound. To determine the genetic cause, the research team performed Whole Exome Sequencing (WES) on the fetus and its parents. The results revealed compound heterozygous variants in the fetal TRIP11 gene: a novel nonsense mutation c.790C>T (p.R264*) inherited from the father, and a novel splice site mutation c.589-2A>G inherited from the mother.
Neither variant had been reported in public databases. Particularly, the c.589-2A>G variant, located at a critical position for splicing, required functional assessment to determine its pathogenicity.
RDDC's Precise Prediction: Revealing Two Disruptive Splicing Patterns
To evaluate the potential pathogenic mechanism of this "Variant of Uncertain Significance" (VUS), the researchers utilized the RDDC RNA Splicing Prediction Model. This AI-based tool accurately predicts the impact of variants on mRNA splicing.
Predicted Splicing Outcomes
For the c.589-2A>G variant, RDDC predicted two primary aberrant splicing outcomes:
- A 10 bp deletion in exon 5: This would cause a frameshift, leading to a premature termination codon.
- Skipping of exon 5: The entire exon 5 would be removed during mRNA maturation.
Protein Function Impact
Both predicted outcomes clearly indicated that this splice variant would severely disrupt the normal processing of RNA, resulting in truncated or structurally abnormal GMAP-210 protein (encoded by TRIP11). Combined with the nonsense mutation inherited from the father, these compound heterozygous variants would lead to a complete loss of GMAP-210 protein function, explaining the lethal ACGIA phenotype in the fetus.
Case Value: Aiding Diagnosis and Genetic Counseling
The clear pathogenic mechanism predicted by the RDDC tool provided strong bioinformatic evidence for the pathogenicity assessment of the c.589-2A>G variant. Although direct in vitro functional validation was lacking in this study, RDDC's prediction, combined with the variant's de novo nature (relative to family history), its critical location at a splice site, and its consistency with the known disease mechanism, allowed it to be reliably classified as pathogenic.
Clinical Significance
This case highlights the value of the RDDC RNA Splicer in interpreting splice site VUS. It provides rapid and reliable functional predictions for novel, rare variants identified by WES, effectively assisting clinicians in pathogenicity assessment. This offers crucial molecular evidence for the precise diagnosis of rare skeletal dysplasias like ACGIA, and informs genetic counseling and prenatal diagnostic strategies (such as screening via assisted reproductive technology).
Disease Background: Achondrogenesis Type IA
Achondrogenesis Type IA (ACGIA) is an extremely rare, lethal skeletal dysplasia primarily caused by mutations in the TRIP11 gene. The disease is characterized by:
- Severe skeletal developmental abnormalities
- Defective cartilage formation
- Usually lethal in the fetal or neonatal period
- Often accompanied by developmental abnormalities in other systems
TRIP11 Gene Function
The TRIP11 gene encodes the GMAP-210 protein, which plays an important role in maintaining Golgi apparatus structure and protein transport. Loss of GMAP-210 protein function leads to abnormal intracellular protein transport, subsequently affecting normal cartilage and bone development.
RDDC Technical Advantages
In this case, the RDDC RNA Splicing Prediction Model demonstrated the following technical advantages:
Advanced AI Algorithm
- Deep learning-based splicing prediction algorithm
- High-precision prediction of functional consequences of splice site variants
- Ability to identify multiple aberrant splicing patterns
Clinical Application Value
- Rapid assessment of VUS pathogenicity
- Providing scientific evidence for genetic counseling
- Assisting prenatal diagnostic decisions
- Reducing unnecessary functional validation experiments
Conclusion
This case successfully demonstrates the important value of the RDDC RNA Splicing Prediction Model in the molecular diagnosis of rare genetic diseases. By accurately predicting the impact of the c.589-2A>G variant on TRIP11 gene splicing, RDDC provided crucial bioinformatic evidence for the pathogenicity assessment of this variant, effectively assisting in the molecular diagnosis of ACGIA.
This successful application not only provided important evidence for genetic counseling and prenatal diagnosis in this family, but also offers valuable experience for other similar rare disease studies. As AI technology continues to develop, bioinformatics tools like RDDC will play increasingly important roles in precision medicine and rare disease diagnosis.
Content Source and Disclaimer
This article is a compilation and interpretation of the scientific study cited below, intended to highlight the application of RDDC bioinformatics tools. All research data and conclusions belong to the original authors and publication.
Original Article:
Chen H¹,², Zhang C¹, Zhou B¹, Chen X¹, Hui L¹. Genetic analysis of a family with achondrogenesis type IA caused by TRIP11 gene variation.
Affiliation: ¹Medical Genetics Center, Gansu Provincial Maternity and Child Health Care Hospital; ²
Year: 2024
